The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 04, 2021

Filed:

Jun. 12, 2020
Applicants:

Crispr Therapeutics Ag, Zug, CH;

Bayer Healthcare Llc, Whippany, NJ (US);

Inventors:

Ryo Takeuchi, Cambridge, MA (US);

Akiko Noma, Cambridge, MA (US);

Shuying He, Cambridge, MA (US);

Abraham Scaria, Cambridge, MA (US);

Assignees:

CRISPR THERAPEUTICS AG, Zug, CH;

BAYER HEALTHCARE LLC, Whippany, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01);
Abstract

The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.


Find Patent Forward Citations

Loading…